Cassava Sciences Inc

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cassava Sciences advances Phase III trial with strong financial footing

Cassava Sciences is progressing well with Phase III trial milestones and financial stability, poised to announce critical trial results by year-end.
While facing challenges in data accuracy and increased expenses, the company's proactive approach and strategic planning present significant growth opportunities.
By focusing on innovation and market transformation, Cassava Sciences is positioned to redefine Alzheimer's disease diagnosis and treatment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

Cassava Sciences has a promising drug candidate for Alzheimer's. However, SAVA stock may be overpriced based on the limited data so far.

Analyzing the Potential Risks of Cassava Sciences

Why Is Cassava Sciences' Stock So Volatile?

Biogen

Who will emerge victorious in the race to help Alzheimer's patients?

Cassava Sciences vs. Biogen

Cassava believes that a mutating protein, Filamin A, is a major culprit behind Alzheimer's disease. The company's drug, simufilam, aims to fix this mutation and restore its proper form and function.

Here's What Investors Should Know About Cassava's Alzheimer's Drug Candidate

Cassava is still pre-revenue but SAVA stock has a flock of strong fans. They bought the dip with gumption, which suggests long-term success.

Bring a Neck Brace When Trading Cassava Sciences

KemPharm

Novan

Onconova Therapeutics

Investing in biotech stocks isn't for the faint of heart, but these can be some of the most lucrative equities on the market. The post How to Pick the Best Small Cap Biotech Stocks to Buy appeared first on InvestorPlace.

How to Pick the Best Small Cap Biotech Stocks to Buy

Annovis Bio

Anavex Life Sciences

Millions of Americans are struggling with Alzheimer's, according to the Alzheimer's Association. The disease often has a slow progression, lasting years or even decades, and it's one of the leading causes of death in the United States.

Use Weakness in these 3 Alzheimer's Disease Stocks as Opportunity

The stock lost $75 a share in two days at the end of the month.

Why Shares of Cassava Sciences Fell 18.6% in July

Cassava Sciences posted positive clinical data but triggered a sell on the news event, as SAVA stock short sellers welcomed the drop. The post What to Do After Cassava Sciences Dropped Off a Cliff appeared first on InvestorPlace.

What to Do After Cassava Sciences Dropped Off a Cliff

SAVA stock is truly worth paying attention to from here forward as data suggests Cassava Sciences may have solved a big mystery. The post Cassava Sciences May Be Revolutionary in the Alzheimer's Fight appeared first on InvestorPlace.

Cassava Sciences May Be Revolutionary in the Alzheimer's Fight

Dynavax Technologies

GT Biopharma Inc

Novavax

Pacific Biosciences of California

Have penny stocks presented some of the biggest opportunities in the stock market? The post Are Penny Stocks Worth It?

Are Penny Stocks Worth It? 5 That Deserve Your Attention Now

Things are changing, but the picture is getting more positive as time goes on.

3 Things About Cassava Sciences That Smart Investors Know

Biogen's Aduhelm performed no better than placebo in non-ApoE4 carriers and only slightly slowed down the progression of Alzheimer's disease in ApoE4 carriers.

Detours In The Golden Age Of Alzheimer's Drug Stock Investments

The stock price of Cassava Sciences Inc (NASDAQ: SAVA) increased by over 17% during intraday trading. This is why it happened.

SAVA Stock Price Increases Over 17% Intraday: Why It Happened

Cassava Sciences stock has been hammered for no good reason and is likely to rebound. AVA stock is still worth over $900 especially given the recent positive 9-month results of its Alzheimer's drug Simufilam.

Cassava Sciences Stock Has Been Hammered For No Good Reason and Is Likely To Rebound

- Conference Call Today at 9 a.m. ET - - Conference Call Today at 9 a.m. ET -

Cassava Sciences Reports Second Quarter 2021 Financial Results

AMC Entertainment

Robinhood

Nikola

These stocks look to be more trouble than they're worth.

5 Ultra-Popular Stocks to Avoid Like the Plague in August

- Call-in on Tuesday, August 3rd at 9 a.m. ET - - Call-in on Tuesday, August 3rd at 9 a.m. ET -

Cassava Sciences Announces Conference Call for Second Quarter Financial Results

Simufilam is the first AD drug to show a cognitive improvement at 9 months, with a gaudy 18% mean improvement from baseline. Simufilam also showed a growing behavioral benefit.

Cassava Sciences' Simufilam Is The First Alzheimer's Drug To Work At 9 Months, And The Benefit Is Growing

The stock price of Cassava Sciences Inc (NASDAQ: SAVA) fell by over 25% during intraday trading. These are some details you should know.

SAVA Stock Fell 23.61%: Details You Should Know

As Cassava Sciences made progress in treating Alzheimer's, SAVA stock is on a powerful path to significantly higher prices. The post Cassava Sciences Stock Has Plenty of Momentum After Positive Clinical Data appeared first on InvestorPlace.

Cassava Sciences Stock Has Plenty of Momentum After Positive Clinical Data

A clinical-trial flop for Annovis Bio is reminding investors that developing new drugs for Alzheimer's disease is an extremely risky business.

Here's Why Annovis Bio, Anavex Life Sciences, and Cassava Sciences Sank on Thursday

AUSTIN, Texas, July 29, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced positive biomarker data from an open-label study of simufilam, the Company's investigational drug for the treatment of Alzheimer's disease.

Cassava Sciences Announces Positive Biomarker Data with Simufilam in Alzheimer's Disease

AUSTIN, Texas, July 29, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) announced positive clinical data today from an interim analysis of an open-label study with simufilam, the Company's investigational drug for the treatment of Alzheimer's disease.

Cassava Sciences Announces Positive Cognition Data With Simufilam in Alzheimer's Disease

This popular life science company has a fair but risky shot of developing a novel drug to treat Alzheimer's disease.

News for Cassava Sciences Inc Stock (SAVA)